retatrutide nejm 2023 obesity trial ly3437943 Retatrutide: Phase 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Retatrutide (LY3437943) — Dosing, Side

In patients 65 years of age, a higher proportion of patients treated with dapagliflozin for glycemic control had adverse reactions of hypotension [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)]

The FDA's enforcement action targeted platforms making claims implying compounded products are equivalent to FDA-approved drugs, making unsubstantiated safety and efficacy claims, or obscuring which entity compounds the medication

doi: 10.1016/j.molmet.2022.101590

Jay Park MD

"Food noise also indicates that obesity is not a mere issue of willpower," she emphasized

Products like Ozempic, Mounjaro, and Zepbound are FDA-regulated injectables